Stock Analysis·← Pickers

SENS

Senseonics Holdings, Inc.

Senseonics Holdings, Inc. (SENS) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 36.5, with 0/3 trend checks passing.

Price
$5.15
2026-07-16
Trend score
0/3
Downtrend
RSI (14)
36.5
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

SENS with MA50 and MA200

11.309.738.156.585.0007/3110/2401/2204/1707/15
SENS2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$6.05-14.87% vs price
MA200
$6.76-23.85% vs price
RSI (14)
36.5Neutral zone
MACD Signal
BearishMomentum below signal
Macro Support
$5.25–$5.410.0% below price · 3 touches
Support Quality
3 touches1.7× zone volume
Chart Summary
Trend summary for SENS

Senseonics Holdings, Inc. (SENS) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $5.15, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 14.9% and below the 200-day moving average by 23.9%.

Momentum and stretch context

SENS currently has an RSI reading of 36.5, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.

What traders may watch next

For traders reviewing SENS next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.

Company profile

About Senseonics Holdings, Inc.

Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.

Sector
Healthcare
Industry
Medical - Devices
CEO
Timothy T. Goodnow
Employees
130
Market cap
$215.2M
Beta
0.99
52-week range
$4.79 – $12.58
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
22 Dec 2015
ISIN
US81727U3032
CUSIP
81727U303
Company profile data from Financial Modeling Prep. SENS listed on NASDAQ.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about SENS

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.

SENS Stock Analysis: Downtrend, below MA50 & MA200, RSI 37 | MyStockHarbor